[{"address1": "5959 Horton Street", "address2": "7th Floor", "city": "Emeryville", "state": "CA", "zip": "94608", "country": "United States", "phone": "510-871-4880", "website": "https://www.metagenomi.co", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.", "fullTimeEmployees": 237, "maxAge": 86400, "priceHint": 4, "previousClose": 3.8, "open": 3.81, "dayLow": 3.34, "dayHigh": 3.905, "regularMarketPreviousClose": 3.8, "regularMarketOpen": 3.81, "regularMarketDayLow": 3.34, "regularMarketDayHigh": 3.905, "forwardPE": -1.0467836, "volume": 178869, "regularMarketVolume": 178869, "averageVolume": 103572, "averageVolume10days": 86430, "averageDailyVolume10Day": 86430, "bid": 3.49, "ask": 3.68, "bidSize": 100, "askSize": 100, "marketCap": 134121832, "fiftyTwoWeekLow": 3.34, "fiftyTwoWeekHigh": 12.74, "priceToSalesTrailing12Months": 2.8380768, "fiftyDayAverage": 6.6542, "twoHundredDayAverage": 8.746739, "currency": "USD", "enterpriseValue": -145221168, "profitMargins": -1.6350701, "floatShares": 23437604, "sharesOutstanding": 37464200, "sharesShort": 228067, "sharesShortPriorMonth": 905182, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0061000003, "heldPercentInsiders": 0.33493, "heldPercentInstitutions": 0.38831002, "shortRatio": 1.57, "shortPercentOfFloat": 0.0084, "impliedSharesOutstanding": 37464200, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -77270000, "forwardEps": -3.42, "enterpriseToRevenue": -3.073, "enterpriseToEbitda": 1.71, "52WeekChange": -0.6527643, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MGX", "underlyingSymbol": "MGX", "shortName": "Metagenomi, Inc.", "longName": "Metagenomi, Inc.", "firstTradeDateEpochUtc": 1707489000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b9b86ae0-a307-38b5-a501-e7048f92be48", "messageBoardId": "finmb_633445224", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.58, "targetHighPrice": 25.0, "targetLowPrice": 10.0, "targetMeanPrice": 19.0, "targetMedianPrice": 21.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 327404992, "totalCashPerShare": 8.739, "ebitda": -84947000, "totalDebt": 48062000, "quickRatio": 4.679, "currentRatio": 4.747, "totalRevenue": 47258000, "debtToEquity": 17.437, "revenuePerShare": 6.029, "returnOnAssets": -0.13588999, "returnOnEquity": -0.28236, "freeCashflow": -51100248, "operatingCashflow": -100264000, "revenueGrowth": 0.289, "grossMargins": -1.23691, "ebitdaMargins": -1.79752, "operatingMargins": -2.60167, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]